Patrick Sartore - ProMetic Life Insider

PJ2 -- Germany Stock  

EUR 0.33  0.017  4.93%

Mr. Patrick Sartore is a Chief Legal Officer and Corporationrationrate Secretary of the Company. Mr. Patrick Sartore joined Prometic in 2006 as Senior Legal Counsel Intellectual Property, was nominated Corporationrationrate Secretary of the Corporationrationration in 2007. Mr. Sartore held the position of General Counsel and Corporationrationrate Secretary from May 2013 to May 2015, at which date he was appointed Chief Legal Officer and Corporationrationrate Secretary. Mr. Sartore was previously employed by Univalor Inc. as Legal Counsel and Leger Robic Richard, L.L.P., a firm specializing in Intellectual Property, Corporationrationrate and Commercial Law, as an associate attorney. Mr. Sartore has extensive experience in the areas of intellectual property, technology transfer, licensing and commercialization, private and public financing as well as general corporate and commercial law, namely in the biopharmaceutical field. Mr. Sartore graduated from the University of Montreal with a Bachelor of Law in 1999 and was called to the Bar of Qubec in 2001
  Executive Since 2015      
Sartore also holds a BS, with Distinction, from Concordia University.

Management Efficiency

The company has return on total asset (ROA) of (29.38) % which means that it has lost $29.38 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (115.8) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 94.87 M in total debt with debt to equity ratio (D/E) of 140.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. ProMetic Life Sciences has Current Ratio of 1.42 which is within standard range for the sector.

Similar Executives

Found 10 records


Vince AnzaloneArrowhead Pharmaceuticals
Patrick OBrienArrowhead Pharmaceuticals
Veronique FoutelDBV Technologies S A
David LewisArrowhead Pharmaceuticals
Wence AgbotounouDBV Technologies S A
Chad RubinArrowhead Pharmaceuticals
Charles RubanDBV Technologies S A
Hugh SampsonDBV Technologies S A
Robert BurrowsEmergent BioSolutions
Bertrand DupontDBV Technologies S A

Entity Summary

ProMetic Life Sciences Inc., a biopharmaceutical company, develops bioseparations, plasma-derived therapeutics, and small-molecule therapeutic products. ProMetic Life Sciences Inc. was founded in 1992 and is headquartered in Laval, Canada. ProMetic Life operates under Biotechnology classification in Germany and traded on Frankfurt Stock Exchange. It employs 480 people.ProMetic Life Sciences (PJ2) is traded on Frankfurt Stock Exchange in Germany. It is located in 440, Boulevard Armand-Frappier and employs 480 people.

ProMetic Life Sciences Leadership Team

Nancy Orr, Independent Director
Louise Menard, Independent Director
Simon Best, Independent Chairman of the Board
Steve Burton, CEO of ProMetic BioSciences Ltd.
Andrew Bishop, Independent Director
Patrick Sartore, Senior Legal Counsel, Corporate Secretary
DwunHou Chen, Senior Vice President Product and Asia Pacific Development of ProMetic BioTherapeutics, Inc.
Bruce Wendel, Director
Gregory Weaver, CFO
Pierre Laurin, President CEO, Director
John Moran, Chief Medical Officer, Director
Stefan Clulow, Director
Kenneth Galbraith, Director
Bruce Pritchard, CFO
Benjamin Wygodny, Director
Raymond Hakim, Independent Director
Charles Kenworthy, Director
Paul Mesburis, Independent Director
Frederic Dumais, Director- Communications and Investor relations

Stock Performance Indicators

Current Sentiment - PJ2

ProMetic Life Sciences Investor Sentiment

Most of Macroaxis users are at this time bullish on ProMetic Life Sciences. What is your perspective on investing in ProMetic Life Sciences? Are you bullish or bearish?
98% Bullish
2% Bearish
Currently Active Assets on Macroaxis
Purchased a lot of shares of
3 days ago
Traded for 156.0
Purchased a lot of shares of
3 days ago
Traded for 156.0
Purchased over 300 shares of
3 days ago
Traded for 9.81
Purchased over 40 shares of
3 days ago
Traded for 74.735
Purchased over 70 shares of
3 days ago
Traded for 36.08
Additionally take a look at Your Equity Center. Please also try Chance of Distress module to get analysis of equity chance of financial distress in the next 2 years.